Elsevier

Clinical Therapeutics

Volume 24, Issue 2, February 2002, Pages 282-297
Clinical Therapeutics

Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study

https://doi.org/10.1016/S0149-2918(02)85024-XGet rights and content

Abstract

Background: In a flare of osteoarthritis (OA) pain, increasing the dose of standard anti-inflammatory or routine analgesic drugs may not be practical because of an increased incidence of side effects. In patients achieving inadequate pain relief from traditional nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase (COX)-2—selective inhibitors, it may be appropriate to add an analgesic agent with a different mechanism of action, thereby targeting multiple components of the pain pathway.

Objective: The addition of tramadol/acetaminophen tablets to existing therapy was compared with the addition of placebo in the treatment of OA flare pain.

Methods: This was a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study. Patients received 1 or 2 tramadol/acetaminophen (37.5 mg/325 mg) tablets QID or matching placebo for 10 days in addition to ongoing NSAID or COX-2—selective inhibitor therapy. The primary outcome measures were average daily pain intensity and average daily pain relief scores from days 1 through 5.

Results: Three hundred eight patients were randomized to tramadol/acetaminophen (n = 197) or placebo (n = 111) and were followed for up to 10 days. Patients had a mean (±SD) age of 60.1 ± 9.87 years, and were predominantly female (71.8%) and white (87.7%). Their mean (±SD) pain visual analog score at baseline was 73.2 ± 11.8 mm, and their mean pain intensity score was 2.4 ± 0.5 (on a scale from 0 = none to 3 = severe). Average daily pain intensity and pain relief scores were significantly improved with tramadol/acetaminophen compared with placebo on the primary assessment of efficacy from days 1 through 5 (both, P < 0.001) and on the assessment of efficacy from days 1 through 10 (both, P < 0.001). Tramadol/acetaminophen was significantly superior to placebo on the patients' and physicians' overall assessments of medication (both, P < 0.001) and on 3 of 4 subscales (pain [P = 0.004], physical function [P = 0.013], and overall [P = 0.008]) of the Western Ontario and McMaster Universities Osteoarthritis Index Questionnaire. The most common treatment-emergent adverse events with tramadol/acetaminophen were nausea, vomiting, and dizziness. No serious adverse events were reported in the tramadol/acetaminophen group.

Conclusion: In this study, addition of tramadol/acetaminophen to NSAID or COX-2—selective inhibitor therapy was well tolerated and effective in the treatment of OA flare pain.

References (29)

  • SK Swan et al.

    Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial

    Ann Intern Med

    (2000)
  • A Whelton

    Renal and related cardiovascular effects of conventional and COX-2 specific NSAIDs and non-NSAID analgesics

    Am J Ther

    (2000)
  • H Kehlet et al.

    The value of “multi-modal” or “balanced analgesia” in post-operative pain treatment

    Anesth Analg

    (1993)
  • Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 Update

    Arthritis Rheum

    (2000)
  • Cited by (0)

    1

    Members of the CAPSS-105 Study Group are listed in the Acknowledgments.

    View full text